Page 289 - Haematologica - Vol. 105 n. 6 - June 2020

Platelet depletion for effective transfusion
However, MPV was slightly but significantly increased, adding to the contradictory discussion in the literature. While some studies failed to observe a difference during depletion,7 we, like others,16 detected an increase of MPV during the thrombocytopenic phase. We hypothesize that the few “remaining” platelets were freshly produced by megakaryocytes that were not yet eliminated. These young platelets are reported to have a higher MPV18 and
are therefore thought to be more reactive.19 Clinically, MPV distinguishes between different etiologies of throm- bocytopenia.20 Thus, it may be a more sensitive biomarker than platelet count in a variety of disorders, yet it is dis- cussed controversially for different diseases. MPV is high- er in patients with acute coronary syndrome (ACS), com- pared to those with non-cardiac chest pain,21 associates with poor prognosis after ACS21 and closely correlates
Figure 7. Comparison of platelet depletion methods. Depletion principle, depletion kinetic and transfusion efficacy are depicted for the iDTR and antibody-based models, as well as possible appli- cations of the iDTR model.
haematologica | 2020; 105(6)
1747